American cutaneous leishmaniasis (ACL) is a complex, multifactorial disease that results from environmental factors such as parasite polymorphism, phlebotomine sandfly components, as well as the host's immune and genetic background. In northeastern Brazil, the endemic area of Corte de Pedra registers the highest incidence of ACL in the state of Bahia (BA). While the incidence of CL in BA varies from 1.5-3.2 per 10,000, the incidence in Corte de Pedra varies from 15-35 per 10,000. The predominant causative species is *Leishmania braziliensis*, which in most cases leads to CL, characterised by one or more ulcers with raised borders, most frequently located on the upper and lower extremities, but also on the head, face and trunk ([@B9]). Although CL is a self-limiting disease, approximately 3-5% of subjects infected with *L. braziliensis* will eventually develop mucosal leishmaniasis (ML) or disseminated leishmaniasis (DL), considered now an emerging form of the disease in the area. [Fig. 1](#f01){ref-type="fig"} demonstrates these different clinical phenotypes, highlighting the sometimes disfiguring nature of the disease and the need to understand the variable disease pathology.

Fig. 1: the study area and spectrum of clinical disease caused by *Leishmania braziliensis* infection in Corte de Pedra, state of Bahia, Brazil. A: typical house and farm area; B: typical cutaneous leishmaniasis lesion characterised by granulomatous background and elevated borders; C: disseminated leishmaniasis, a form of disease that is increasing in the study area; D: mucosal leishmaniasis characterised by infiltrated ulcers that can cause extensive destruction of the nasal septum, columella and the upper lip.

A number of studies on ACL conducted in Corte de Pedra in the past 30 years have contributed enormously to the knowledge of ACL epidemiology and immune response ([@B20], de [@B28]). Particularly in the last decade, a number of studies evaluating both parasite and host polymorphisms have demonstrated that genetic factors are associated to different clinical forms, revealing relevant biomarkers to understanding the disease pathogenesis ([@B70], [@B25], [@B24], [@B23], [@B22], [@B56], [@B55]). Here we present a narrative review of host genetic studies of ACL conducted in Corte de Pedra over the last decade. Although there are a number of studies evaluating candidate genes in ACL ([Table I](#t01){ref-type="table"}), no genome-wide association studies have so far been reported that would provide a comprehensive map of genetic risk factors for this disease. This is in contrast to host genetic analysis of visceral leishmaniasis (VL), for which a well-powered genome-wide association study was recently reported ([@B33]). Here we will focus on genetic susceptibility to ACL, beginning with the demonstration of familial aggregation of ACL disease in Corte de Pedra that led to analysis of specific candidate genes arising both from our knowledge of immune responses to human *L. braziliensis* infection, and through consideration of wound healing genes that was inspired initially by studies in mice ([@B64], [@B65], [@B63]). These data are further discussed in relation to studies of genetic susceptibility to CL in other geographic regions, as summarised along with all published ([@B8], [@B45], [@B54], [@B31], [@B19], [@B44], [@B52], [@B25], [@B24], [@B23], [@B22], [@B43], [@B48], [@B66], [@B1], [@B2], [@B56], [@B67], [@B51], [@B34], [@B26]) data on susceptibility to CL in [Table I](#t01){ref-type="table"}. One factor that affects interpretation of all of these studies is the issue of sample size and power, which we will return to in our concluding remarks.

TABLE ISummary of published genetic association studies for cutaneous leishmaniasisPapers reporting significant linkage or association  Candidate genePopulationPhenotypeSample sizeReported resultReferencePMIDMHC region (class I-III)Cw7SE Asian HmongCLNAp = 0.01Barbier et al. (1987)3478848A28; Bw22VenezuelanLCL24 familiesp = 0.0018; 0.0122Lara et al. (1991)2022495Bw22VenezuelanLCLCa = 26; Co = 26RR = 12.5; p = 0.048Lara et al. (1991)2022495DQw8VenezuelanLCL24 familiesp = 0.0364Lara et al. (1991)2022495DQw3VenezuelanLCLCa = 26; Co = 26RR = 4.25; p = 0.036Lara et al. (1991)2022495DR2BrazilianMCLCa = 43; Co = 111RR = 0.07; p = 0.004Petzl-Erler et al. (1991)1783572DQw3BrazilianMCLCa = 43; Co = 111RR = 4.2; p = 0.006Petzl-Erler et al. (1991)1783572DR2; DR7/DRw9VenezuelanCLCa = 49; Co = 43p \< 0.05Cabrera et al. (1995)7595196LTAVenezuelanMCLCa = 25; Co = 43RR = 7.5; p \< 0.001Cabrera et al. (1995)7595196TNF (-308)VenezuelanMCLCa = 25; Co = 43RR = 3.5; p \< 0.05Cabrera et al. (1995)7595196DRB1\*0407; DPA1\*0401; DPB1\*0101Mexican mestizosLCLCa = 65; Co = 100OR = 2.92, 10.07, 5.99Olivo-Diaz et al. (2004)15041165DPB1\*0401; DR2Mexican mestizosLCLCa = 65; Co = 100OR = 0.38, 0.14Olivo-Diaz et al. (2004)15041165Non-MHC candidate genes      *IL6*-174BrazilianMLCa = 60; Co = 180OR = 2.29 (1.40-3.77); p = 0.001Castellucci et al. (2006)16845637IFNG+874IranianChronic CLCa = 58; Co = 688χ^2^ = 12.53; p = 0.0019Kamali-Sarvestani et al. (2006)16950634*IL-4*-590IranianLCLCa = 201; Co = 92χ^2^ = 8.64; p = 0.003Kamali-Sarvestani et al. (2006)16950634*IL-10*-819BrazilianCL30 familiesOR = 2.5 (1.12-5.7); p = 0.003Salhi et al. (2008)18424735CXCR1 rs2854386BrazilianCLCa = 60; Co = 60OR = 2.38 (1.23-4.57); p = 0.009Castellucci et al. (2010)20089160CXCR1 rs2854386BrazilianML104 familiesp = 0.046Castellucci et al. (2010)20089160SLC11A1 rs17235416BrazilianCL104 familiesp = 0.011Castellucci et al. (2010)20089160CCL2-2518BrazilianMLCa = 67; Co = 120OR = 4.40 (1.42-13.65); p = 0.010Ramasawmy et al. (2010)20430117FLI1 rs7930515BrazilianCL209 transmissionsOR = 1.62 (1.26-2.09); p = 1.8 x 10^-4^Castellucci et al. (2011)21633373TLR4 Asp299GlyIranianChronic CLCa = 22; Co = 75OR = 25.3 (5.2-115.6); p \< 0.001Ajdary et al. (2011)21056683TLR4 Asp299GlyIranianAcute CLCa = 61; Co = 75OR = 8.03 (1.7-37.7); p = 0.006Ajdary et al. (2011)21056683TLR4 Thr399IleIranianChronic CLCa = 22; Co = 75p \< 0.001Ajdary et al. (2011)21056683TLR4 Thr399IleIranianAcute CLCa = 61; Co = 75p = 0.016Ajdary et al. (2011)21056683CTGF rs6918698BrazilianCL271 transmissionsOR = 1.67 (1.10-2.54); p = 0.016Castellucci et al. (2012)22554650FLII rs2071242BrazilianCL268 transmissionsOR = 1.60 (1.14-2.24); p = 0.005Castellucci et al. (2012)22554650TGFBR2 rs1962859BrazilianCL295 transmissionsOR = 1.50 (1.12-1.99); p = 0.005Castellucci et al. (2012)22554650SMAD2 rs1792658BrazilianCL210 transmissionsOR = 1.57 (1.04-2.38); p = 0.03Castellucci et al. (2012)22554650SMAD7 rs4464148BrazilianCL278 transmissionsOR = 2.80 (1.00-7.87); p = 0.05Castellucci et al. (2012)22554650SMAD3 rs1465841BrazilianML52 transmissionsOR = 2.15 (1.13-4.07); p = 0.018Castellucci et al. (2012)22554650SMAD7 rs2337107BrazilianML50 transmissionsOR = 3.70 (1.27-10.7); p = 0.016Castellucci et al. (2012)22554650*IL-1β*-511Mexican mestizosLCLCa = 58; Co = 123OR = 3.23 (1.2-8.7); p = 0.0167Fernández-Figueroa et al. (2012)22629474MIF-173BrazilianCLCa = 110; Co = 682OR = 1.79 (1.15-2.78); p = 0.008Covas et al. (2013)23068083Papers reporting no significant linkage or association  Candidate genePopulationPhenotypeSample sizeReported resultReferencePMIDMHC region (class I-III)TNF rs1800629Sri LankanCLCa = 200; Co = 200NSSamaranayake et al. (2010)20214763LTA rs909253Sri LankanCLCa = 200; Co = 200NSSamaranayake et al. (2010)20214763Non-MHC candidate genes     IFNG+874BrazilianCLCa = 136; Co = 609NSMatos et al. (2007)17456233SLC11A1 rs2276631Sri LankanCLCa = 200; Co = 200NSSamaranayake et al. (2010)20214763SLC11A1 rs3731865Sri LankanCLCa = 200; Co = 200NSSamaranayake et al. (2010)20214763SLC11A1 rs17235409Sri LankanCLCa = 200; Co = 200NSSamaranayake et al. (2010)20214763TLR2 Arg753GlnIranianCLCa = 84; Co = 120NSAjdary et al. (2010)20388552TLR2 Arg677TrpIranianCLCa = 84; Co = 120NSAjdary et al. (2010)20388552FcyRIIA-H/R131BrazilianCLCa = 88; Co = 98NSOliveira et al. (2011)21324097[^1]

*The endemic site of Corte de Pedra* - Corte de Pedra, a village located in the southwestern region of BA, belongs to the municipality of Presidente Tancredo Neves, whose population is approximately 17,928 inhabitants (source: Brazilian Institute of Geography and Statistics). The endemic area of Corte de Pedra, however, extends far beyond the village, covering 20 municipalities in a total area of approximately 9,935 km^2^ around the site where a Health Post was established in 1980s as a reference centre for the treatment of leishmaniasis in the region. Currently, 430,347 people are distributed across these towns, for which the main economic activity is subsistence farming, particularly the cultivation of cocoa, cloves, guarana, banana, coffee, black pepper and rubber. The endemic area of Corte de Pedra is typically an area of rainforest that over the years has been reduced to isolated areas of secondary forest with agricultural activities providing the main source of income for the majority of its inhabitants. The occupational and domestic habits of these individuals, which involve work on farms and homes built in clearings in the woods, have increased the population's exposure to *L. braziliensis*infection. From 2007-2012, 7,093 cases of ACL were recorded in the region, with 6,747 (95%) cases of CL, 138 (2%) cases of ML and 208 cases (3%) cases of DL.

*A familial aggregation study* - It is well known that the clinical outcome of parasitic infections is influenced by the complex interaction of parasite strain, host genetics and environmental factors. Leishmaniasis, in particular, has a broad clinical spectrum associated with variable profiles of immune response and different *Leishmania* species ([@B19], [@B3], [@B57]). Previous studies have described familial clustering of VL and CL ([@B3], [@B14], [@B42]). Given that ML is a rare phenotype associated with a vigorous inflammatory response to parasite antigens ([@B7]), we conducted a study to address the hypothesis that familial clustering of ML would occur in the endemic area of Corte de Pedra. The study was a reconstructed cohort, a hybrid between a case-control and a retrospective cohort study. All members of 30 ML and 30 neighbourhood control families were assessed for history of exposure, as assessed by positive delayed type hypersensitivity (DTH) response and/or current or past disease confirmed from medical records or by clinical examination for presence of a scar in association with a positive DTH response. First-degree relatives of index cases were compared with those of index controls ([@B21]). There were significant differences between the frequencies of CL (37% vs. 20%) and ML (5% vs. 0%) when comparing case families and control families, respectively. Additionally, families with two cases of ML had a higher frequency (29.6%) of DTH-positive individuals than control families (9.4%). In this way we documented familial aggregation of CL and ML in a region where *L. braziliensis*is highly endemic. Although shared environment reflecting the rate of exposure to sandflies, the number of parasites inoculated by the infected sandflies, pre-existing immune responses to sandfly saliva products and variation between isolates of *L. braziliensis*([@B39], [@B37]) could contribute to this familial aggregation, our data favoured the hypothesis that genetic background could be influencing a higher rate of infection and/or a propensity to develop or retain a positive skin test in family members. This was supported by our failure to detect differences between ML and neighbourhood control families for environmental factors evaluated in our study area. At the same time, other studies were already documenting ([Table I](#t01){ref-type="table"}) host genetic factors influencing the immune response and clinical outcome of leishmaniasis in mice and humans ([@B14], [@B13]). Based on these findings, we conducted a number of candidate gene studies in order to identify polymorphic markers associated with ACL in the Corte de Pedra population.

*Analysis of candidate immune response genes* - The first series of candidate gene studies undertaken in our study area were based on analysis of candidate immune response genes informed by our knowledge of the immunopathology of disease. These studies were initially based on a case-control study design, where possible supported by family-based analysis to control for ethnic admixture. Both cohorts were geographically and demographically equivalent. [Table II](#t02){ref-type="table"} describes the structure of case-control and family sample sets used as a resource for these candidate gene studies.

TABLE IICharacteristics of collections made during the primary (2000-2004) and secondary (2008-2010) sampling periods (A) and demographic data of the case-control groups (B)APrimary sample periodSecondary sample periodCLMLLeishmaniasis *per se*CLMLLeishmaniasis *per se*Cases (n)2508733740239441Males1286018821924243Females1222714918315198Age at disease (years)      Mean19.130.322.421.526.621.995% confidence interval17.1-21.225.8-34.320.3-24.420.1-22.920.7-32.420.6-23.3Nuclear families (n)\--168\--157Total families/trios (n)\--767\--764BMLCLUnaffected controlDTH+Individuals (n)60606060Age range (years)11-6910-8011-7512-75Mean age (years) ± SD40 ± 17.141 ± 17.840 ± 18.038 ± 18.0Males:females47:1347:1347:1347:13Mean time residing in study area ± SD27 ± 16.931 ± 18.229 ± 17.432 ± 17.7Farm as main occupation (%)80706875[^2]

*Interleukin (IL)-6* - ML is a severe disease that normally follows localised CL. Immune pathology is created by a strong pro-inflammatory response with high levels of tumour necrosis factor (TNF) and failure of type 2 cytokines to regulate this response. IL-6 down-regulates T helper (Th) cell type 1 differentiation and drives Th2 cell differentiation. Previous studies have shown that pre-treatment with recombinant human IL-6 inhibits interferon (IFN)-γ and TNF mediated activation of human macrophages for killing of *L. amazonensis*([@B40]) and IL-6 has been shown to down regulate the expression of TNF membrane receptors ([@B10]). We evaluated ([@B25]) the functional *IL6*-174 bp G/C promoter polymorphism, a single nucleotide polymorphism (SNP) associated with pro-inflammatory diseases and IL-6 regulation ([@B35], [@B12], [@B74]). In addition, IL-6 levels were measured in macrophages with or without stimulation with soluble *Leishmania* antigen (SLA) from *L. braziliensis.* Our data ([@B25]) provide both population-based \[odds ratio (OR) = 2.29, 95% confidence intervals (CI) = 1.40-3.77, p = 0.001\] and family-based (z = 4.3, p = 1.5 x 10^-5^) evidence for an association between the C allele of the -174 bp SNP at *IL6*and susceptibility to ML. The family-based analysis was important in confirming that the association was not due to population substructure that might have differed between case and control groups. In addition, we found that the C allele was associated with reduced baseline expression of IL-6 in unstimulated macrophages and in macrophages stimulated with SLA. There are inconsistencies among studies concerning the role of the*IL6*-174 bp G/C polymorphism, both in terms of which is the disease-associated allele, and when attempting to determine whether different genotypes are functionally associated with the production of differing IL-6 levels. The fact that IL-6 has many pleiotropic effects in regulating both type 1 and type 2 immune response pathways ([@B30]), plus the complexities of the immunopathogenesis of these different diseases ([@B58], [@B29]), might explain such differences. Besides, it is important to bear in mind that the -174 bp SNP is not the sole polymorphic determinant of differential and cell type-specific promoter activity driving *IL6*gene transcription ([@B35], [@B74]). In relation to our own study, as macrophages are the primary site of infection, we hypothesise that low IL-6 production in carriers of the C allele may contribute to a reduced capacity to induce Th2 cell differentiation and regulate the activity of CD4^+^ Th1 cell-generated cytokines (such as IFN-γ and TNF) that contribute to the destructive pathological manifestations associated with ML.

*CCL2/MCP1* - There are several reports for the putative roles of the *CCL2*-encoded monocyte chemoattractant protein-1 (MCP-1) in leishmaniasis from infection studies in vitro ([@B59], [@B11]) as well as by analysis of human ([@B60]) and murine (de [@B27]) lesions. Previous studies have variably demonstrated increased risk or protection from pulmonary tuberculosis associated with single SNP variants and/or different haplotypes created by promoter region SNPs at -362 bp and at -2,518 bp ([@B36], [@B77], [@B41]). One of these studies ([@B36]) further showed that tuberculosis patients carrying the G allele for the SNP at -2,518 bp had the highest plasma levels of MCP-1 and the lowest plasma levels of IL-12p40, which was therefore interpreted as a secondary effect of MCP-1 in impairing the Th1 immune response against *Mycobacterium tuberculosis*. We also demonstrated ([@B56]) that the G allele at the regulatory *CCL2*-2,518 bp promoter is a risk factor for ML using our population-based (OR = 4.4, 95% CI = 1.42-13.65, p = 0.01) and family-based (z = 2.68, p = 0.007) samples (Table II) from Corte de Pedra. A number of studies suggest a link between the leishmanicidal capacity of MCP-1 and lesion healing. Previous work has demonstrated that MCP-1 enhances the cytotoxic response *via* induction of reactive oxygen intermediates by infected macrophages ([@B59], [@B11]). Moreover, in patients with self-healing CL, high levels of MCP-1 were detected in infected skin whereas, in the non-healing lesions of diffuse CL, MCP-1 expression was much lower with a predominance of another CC chemokine, CCL3 or macrophage inflammatory protein 1-α (MIP-1α) ([@B60]). In addition, it was demonstrated that the chemokines MCP-1, MIP-1α and CXCL1 were expressed in ears and draining lymph nodes of mice infected in the ear with *L. braziliensis*(de [@B27]). Our results suggest that high levels of MCP-1 appear to exacerbate ML disease. In contrast to previous data ([@B36]), plasma levels of IL-12p40 and IL-12p70 did not differ significantly between our *CCL2*-2,518 bp genotype groups. We also observed higher MCP-1 levels in the supernatants of macrophages from GG compared to AA genotypes both in un-stimulated as well as SLA and LPS stimulated cultures. Our data support the alternative view that the proinflammatory capacity of MCP-1 in recruiting host monocytes could provide both the environment for parasite replication and for tissue damage and lesion development. This could be due to a direct effect of MCP-1 in bringing fresh monocytes to the site of infection and/or to downstream events regulated by MCP-1 in macrophages and other cells.

*CXCR1 and SLC11A1* - It has been hypothesised ([@B53]) that differences in the ability of macrophages and dendritic cells from different inbred mouse strains to respond to apoptotic vs. necrotic polymorphonuclear leukocytes (PMN), arising during the wound healing response to an infected sandfly bite, determines disease progression. The arrival and maintenance of infiltrating cells at bite sites is thought to be mediated by sandfly derived factors that either mimic a tissue damage signal or activate chemokine/chemokine receptor pathways ([@B71], [@B72], [@B73]). Expression patterns for chemokines have been associated with the evolution of large and small lesions in mice following *L. braziliensis* infection, influenced by both the strain of parasite ([@B72]) and the mouse genetic background ([@B71]). One way to look at the interplay between PMN and macrophages in disease progression in humans is to determine whether polymorphisms at genes that regulate their infiltration or function are associated with different clinical phenotypes following infection with *Leishmania*spp. *CXCR1* (IL8RA) and *CXCR2* (IL8RB) are genes encoding receptors for chemokines that attract PMN to inflammatory sites. They lie on human chromosome 2q25 230-260 kb upstream of *SLC11A1*, a gene that regulates macrophage activation and resistance to VL ([@B16]). In our studies ([@B24]), we showed an association between ACL and polymorphic variants at the *CXCR1*, specifically at SNP rs2854386 for both population-based (OR = 2.38, 95% CI = 1.23-4.57, p = 0.009) and family-based (z = 2.00, p = 0.045). Of interest, the common C allele (presumed to be the functional variant) was associated with CL, whereas the rare G allele was associated with ML (z = 2.00, p = 0.046). This suggested that, whereas high numbers of PMN might be detrimental in the context of CL disease, they may have an important positive role to play in preventing ML disease. In addition, in the family-based study CL was associated (z = 2.55, p = 0.011) with a 3' insertion/deletion polymorphism at *SLC11A1*, a gene primarily known for its role in the regulation of macrophage activation. The association is also of interest in relation to the putative role of this molecule in regulating expression of secretory leukocyte protease inhibitor and hence affecting the wound healing response ([@B76]). Differences in lesion development have not been observed following subcutaneous needle injection of either *Leishmania major* ([@B4]) or *Leishmania mexicana* ([@B61]) into *Slc11a1* congenic mice, suggesting that the genetic influence of *SLC11A1* on susceptibility to CL following natural infection in humans might be mediated by the effect on the wound healing response to the sandfly bite. This means that the mechanism by which *SLC11A1* influences CL disease may be different to its influence on VL in mice following intravenous needle injection ([@B17]) or in natural infection of dogs ([@B68], [@B69]) and humans ([@B18], [@B49]). Our data supports roles for both *CXCR1* and *SLC11A1* in determining the outcome of *L. braziliensis* infection, providing interesting insight into the possible roles of PMN and macrophages in ACL.

*The wound healing gene hypothesis: studies inspired by mice* - Our observations on the possible role of wound healing genes in response to sandfly delivered parasites were not the first to suggest a possible role for wound healing genes in CL susceptibility. Indeed, our interpretation was based largely on the seminal mapping studies of susceptibility to CL carried out in mice ([@B64], [@B65], [@B63]), which inspired us to look for the possible role of these and other wound healing genes in susceptibility to ACL in Corte de Pedra.

*FLI1* - Fine mapping in the region of chromosome 9 in mice (chromosome 11q24 in humans) identified Friend leukaemia virus integration 1 (*Fli1*) (*FLI1* in humans) as a novel candidate influencing both resistance to *L. major* and an enhanced wound healing response ([@B63]). To determine whether polymorphisms at *FLI1* were important in human disease, SNPs that tagged the first two major linkage disequilibrium blocks and the proximal promoter of the *FLI1*gene were analysed in 325 endemic *L. braziliensis* families ([@B23]). The proximal promoter region of *FLI1* contains a functional GAn microsatellite, as well as a CpG island that spans the proximal promoter region and the 5′ region of intron. Using robust case-pseudocontrol conditional logistic regression analysis of discovery (OR = 1.65, 95% CI = 1.18-2.29, p = 0.003) and replication (OR = 1.60, 95% CI = 1.10-2.33, p = 0.014) family-based cohorts, we demonstrated association between *FLI1*(rs7930515; *P* ~combined~ = 1.8 x 10^-4^) and susceptibility to CL caused by *L. braziliensis*([@B23]). In the murine study, resistance to *L. major*correlated with a wound-healing response that presented in congenic resistant mice as a large population of fibroblasts and an organised and abundant deposition of collagen bundles in the absence of inflammatory cells ([@B64]). Recent studies have shown an association between enhanced type I collagen expression and epigenetic repression of the *FLI1*gene ([@B79]). As reviewed above, our group also reported an association between ML and the C allele at the *IL6*-174 bp G/C promoter polymorphism ([@B25]), which determines low levels of IL-6 release from macrophages. Homocysteine dependent stimulation of IL-6 has recently been reported ([@B75]) to upregulate genes essential for epigenetic DNA methylation *via* expression of *FLI1*. Homocysteine increases the CpG methylation status (and hence represses gene expression) of the CpG-rich proximal promoter of the lysyl oxidase (*LOX*) gene ([@B75]), an extra-cellular copper enzyme that initiates the cross-linking of collagens and elastins. Inhibition of IL-6 reverses this repression. Regulation of collagen expression and organisation may thus involve epigenetic regulation at both *FLI1*and *LOX*genes, consistent with the presence of the CpG island across the region of the functional *FLI1*promoter elements. This suggests that, although there are many immune-related functions for both IL-6 and *FLI1* that could account for association with CL caused by *L. braziliensis*, there may be a direct functional link between these two genes that mediates resistance or susceptibility to infection through the wound-healing response. This, in turn, might provide novel therapeutic opportunities.

*Transforming growth factor β (TGFβ) signalling pathway* - IL-6 is known to increase expression of FLI1 ([@B75]). In the wound healing response, both FLI1 ([@B50]) and IL-6 ([@B38]) repress connective tissue growth factor (CTGF) and all three genes interact with the TGFβ pathway. We therefore interrogated further the possible roles of wound healing pathways in cutaneous forms of leishmaniasis caused by *L. braziliensis* by looking for genetic associations with polymorphisms in other genes through interaction with FLI1 and the TGFβ signalling pathway ([@B22]). Robust case-pseudocontrol conditional logistic regression analysis showed associations between CL and SNPs at *CTGF*(rs6918698, OR = 1.67, 95% CI = 1.10-2.54, p = 0.016), *TGFBR2*(rs1962859, OR = 1.50, 95% CI = 1.12-1.99, p = 0.005), *SMAD2*(rs1792658, OR = 1.57, 95% CI = 1.04-2.38, p = 0.03), *SMAD7* (rs4464148, OR = 2.80, 95% CI = 1.00-7.87, p = 0.05) and *FLII*(rs2071242, OR = 1.60, 95% CI = 1.14-2.24, p = 0.005) and between ML and SNPs at *SMAD3* (rs1465841, OR = 2.15, 95% CI = 1.13-4.07, p = 0.018) and *SMAD7*(rs2337107, OR = 3.70, 95% CI = 1.27-10.7, p = 0.016). There is a complex interplay between FLI1 and the TGFb signalling pathway in regulating collagen deposition and fibrosis during the wound healing process. In looking for genetic associations that might throw light on how those genes are influencing the wound healing processes important in CL vs. ML disease caused by *L. braziliensis*, our results indicate that CTGF regulated *via* the SMAD2 arm of the TGFβ signalling pathway is required for wound healing in CL disease. In contrast, ML disease was associated with polymorphism in *SMAD3*, suggesting that alternative regulation of gene expression *via* the TGFβ signalling pathway may lead to ML disease. [Fig. 2](#f02){ref-type="fig"} provides a model for how polymorphisms at genes regulating the different signalling pathways might influence CL and ML disease. Further functional data will be required to determine what the downstream events following signalling *via* SMAD3 in ML compared to signalling *via* SMAD2 for CL disease might be. Additionally, both forms of disease were influenced by polymorphisms in the negative regulator *SMAD7* that blocks the TGFβ pathway upstream of both SMAD2 and SMAD3 emphasising the relevance of TGFβ signalling on ACL.

Fig. 2: diagram of genes that have been implicated in susceptibility to cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML) disease caused by *Leishmania braziliensis* in the area of Corte de Pedra, state of Bahia, Brazil, showing involvement of, and interaction with, the transforming growth factor β (TGFβ) pathway. Polymorphisms in genes annotated in red lettering have been associated with CL or ML disease. Turquoise circles indicate the pathway through which interleukin (IL)-6 influences SMAD4 *via* FLI1. SP1/3 are transcription factors that influence FLI1 expression. CTGF: connective tissue growth factor. Source: Castellucci et al. (2012).

*Leishmania* infection is associated with a broad spectrum of clinical phenotypes. *L. braziliensis*, in particular, causes debilitating and disfiguring CL, ML and DL that generally take a long time to heal. For over 50 years, pentavalent antimony (Sb^v^) given by the intramuscular or intravenous route remained the first-line drug for the treatment of ACL. This therapy can cause toxic side effects and is difficult to administer in poor rural areas ([@B47]). In Corte de Pedra, cure rates after Sb^v^ therapy are becoming increasingly lower and vary from 50-90% ([@B62], [@B78]). In light of this, identifying important pathways/mechanisms of disease can lead to new therapeutic targets and more efficient intervention strategies that aim to increase adherence to treatment in areas with limited access to health services. Genetic studies in humans provide a potentially powerful route to understanding novel pathways of disease pathogenesis that could provide new chemotherapeutic targets.

Whilst broadly driven by parasite species, many studies have implicated host genetics in determining the outcome of infection within each species ([@B32], [@B46], [@B15], [@B65]). Nevertheless, the only definitive study carried out in humans to date was the recent genome-wide association study on VL ([@B33]), which demonstrated that polymorphisms within the DRB1-DQA1 class II region of human leukocyte antigen were the only SNPs to attain genome-wide significance. Remarkably, this finding crossed the epidemiological divide of parasite species (*Leishmania donovani* and *Leishmania chagasi*) and geography (Indian and Brazil) and has important implications for the development of molecularly defined vaccines. While candidate gene studies ([Table II](#t02){ref-type="table"}) have implicated a broader array of genes in susceptibility to CL, these are compromised by lack of power and failure to obtain replication within and between populations. Large well-powered genome-wide studies with replication will be required to evaluate the real significance of these findings. It is of interest, nevertheless, that our studies of ACL have provided evidence in support of important roles for immune response genes involved in wound healing, which are underpinned by initial genetic studies in murine models of disease. These wound healing genes may provide novel therapeutic opportunities in ACL, not the least because there may already be great interest in the same genes as therapeutic targets for other skin disorders. For example, the use of imatinib mesylate has been proposed for treatment of systemic sclerosis ([@B5], [@B6]), an autoimmune disorder similarly resulting from immune activation, fibrosis development and damage of small blood vessels, in which FLI1 is down regulated through an epigenetic mechanism ([@B6]). Imatinib mesylate reverses the expression levels of FLI1. Similar opportunities might apply in the case of other genes that we have demonstrated are associated with the spectrum of ACL disease. Work is in progress to analyse expression levels of FLI1 and other wound healing genes in tissue biopsies from *L. braziliensis* patients to determine their potential as therapeutic targets, along with plans to undertake well-powered genome-wide association studies to validate our genetic findings for this important tropical infectious disease.
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[^1]: PubMed search term: leishmaniasis and susceptibility not drug; field: text word; limits: humans. Human leukocyte antigen notation is as reported in the original papers and has not been updated to current nomenclature as resolution is influenced by the typing method employed at the time. Ca: cases; CL: cutaneous leishmaniasis; Co: controls; DCL: diffuse CL; IFN: interferon; IL: interleukin; LCL: localised CL; LTA: leishmaniose tegumentar americana; MCL: mucocutaneous leishmaniasis; MHC: major histocompatibility complex; ML: mucosal leishmaniasis; NA: not available; NS: not significant; OR: odds ratio; PMID: PubMed identifier; RR: relative risk; Th: T helper; TNF: tumour necrosis factor.

[^2]: CL: cutaneous leishmaniasis; DTH: delayed type hypersensitivity; ML: mucosal leishmaniasis; SD: standard deviation.
